Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab

ConclusionPlasmaHER2 amplification detected by ddPCR changed over time and predicted resistance to CTX, by an average lead time of 2  months. Further study is needed to validate our findings.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research